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While sex differences in schizophrenia have long been reported and discussed, long-term sex differences in outcomes among first
episode of psychosis (FEP) patients in terms of the efficacy of Early Intervention Services (EIS) has been an under-explored area. A
total of 209 FEP patients (95 females and 114 males) were reassessed after a time window ranging from 8 to 16 years after their first
contact with an EIS program (PAFIP) that we will call the 10-year PAFIP cohort. Multiple clinical, cognitive, functioning, premorbid,
and sociodemographic variables were explored at 1-year, 3-year and 10-year follow-ups. At first contact, females were older at
illness onset, had higher premorbid adjustment and IQ, and were more frequently employed, living independently, and
accompanied by a partner and/or children. Existence of a schizophrenia diagnosis, and cannabis and alcohol consumption were
more probable among men. During the first 3 years, women showed a significantly better response to minimal antipsychotic
dosages and higher rates of recovery than men (50% vs. 30.8%). Ten years later, more females continued living independently and
had partners, while schizophrenia diagnoses and cannabis consumption continued to be more frequent among men. Females also
presented a lower severity of negative symptoms; however, functionality and recovery differences did not show significant
differences (46.7% vs. 34.4%). Between the 3- and 10-year follow-up sessions, an increase in dosage of antipsychotics was observed.
These results suggest that the better outcomes seen among women during the first 3 years (while they were treated in an EIS) were
in the presence of more favourable premorbid and baseline characteristics. After an average period of 10 years, with the only
difference being in negative symptoms course, outcomes for women approximated those of men, drawing particular attention to
the increase in dosage of antipsychotic medication once FEP patients were discharged from the EIS program towards community-
based services. These findings help to pose the question of whether it is advisable to target sexes and lengthen EIS interventions.
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INTRODUCTION
It is commonly believed that women with schizophrenia have
better disease courses and better overall outcomes than men. A
substantial proportion of male patients have poor long-term
outcomes, namely, low-level functioning, unemployment, and
substance abuse1. A later age-at-onset for females has been
suggested as a factor involved in sex differences in incidence and
course of illness2. However, Seeman et al.3, reported that women’s
better outcomes declined over time and approached those of
men. Further investigation is thus merited, particularly given the
marked heterogeneity previously reported4 in functional out-
comes among first episode of psychosis (FEP) patients, the
possible design bias towards samples with poor outcomes5, and
the lack of long-term studies on sex perspectives.
The studies that explored short-term and long-term (8 years or
more considering the Morgan et al.5 definition) sex-outcome
differences in FEP patients have produced mixed results. A study
carried out in Hong Kong with young people suffering from an
FEP6 found notable sex differences in functional outcomes,
specifically in terms of higher levels of functioning in women
(i.e., higher proportion of fulltime employment) within the initial 3
years of Early Intervention Services (EIS). However, in a recent
observational study, Dama et al.7, found that sex differences in
outcomes among patients treated over 2 years in an EIS for
psychosis in Canada could be largely affected by the disparity of
other factors that exist between the two sexes (i.e., childhood and
early adolescent premorbid adjustment, and age at onset of
psychosis). In the Danish OPUS trial, designed for 2-, 5-, and
10-year follow-ups, it was found that almost 30% of all FEP
patients improved their outcomes between 5-year and 10-year
follow-ups, indicating that improvement is still possible late in
illness course8,9. These findings were similar to those reported in
AESOP-10 (Etiology and Ethnicity in Schizophrenia and Other
Psychosis 10-year follow-up), wherein three course and outcome
domains (clinical, social, and service use) were worse for men5.
Morgan et al.5, noted that symptom remission and recovery are
more common than social re/integration following an FEP. But
both OPUS and AESOP cohort studies suggest that short-term and
long-term outcomes may differ. To the best of our knowledge, no
study has specifically explored long-term sex differences in FEP
patients after being discharged from an EIS for psychosis.
The aims of the present study were to explore in detail long-
term sex differences among FEP patients through several outcome
measures (clinical, functioning, cognition, and treatment); and to
confirm/disconfirm if the positive effects achieved through
treatment in an EIS may similarly last long-term for males and
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females once they are transferred to regular care. We hypothe-
sized that after an average time of 10 years after an FEP, outcomes
in women and men would be very similar.
RESULTS
Between 2001 and 2008, 307 FEP patients were assessed for
baseline PAFIP measures. Of these, 297 were re-tested at 1-year
follow-up, and 259 at 3-year follow-up (See the flowchart of the
study in Fig. 1). From the initial sample, 209 were tested after a
time window ranging from 8 to 16 years (183 by in-person
interview and 26 by telephone). Non-completers significantly had
lower education level (61% vs. 44% elementary studies; p= 0.005),
lived in urban areas (82% vs. 68%; p= 0.011), were unemployed
(54% vs. 38%; p= 0.012), and were cannabis users (56% vs. 36%;
p= 0.001). On the contrary, completers presented more severe
depressive symptoms at baseline (F= 2.114; p= 0.035). A
tendency towards higher participation in 10-year reassessment
was found in women as well as more exitus among men
(Information available in Supplementary Tables 1 and 2).
When comparing male and female FEP patients (95 females and
114 males) who completed the 10-year follow-up assessment,
females were older at admission and at illness onset (31 years vs.
27 years; p < 0.001); had higher premorbid functioning during
childhood, adolescence, and adulthood; presented higher pre-
morbid IQ and education level; lived more frequently indepen-
dently of parents (58% vs. 40%; p= 0.008), were employed (72%
vs. 53%; p= 0.005), and had a partner (23% vs. 13%; p= 0.059)
and children (40% vs. 14%; p < 0.001). Schizophrenia diagnosis
(51% vs. 69%; p= 0.009), alcohol (33% vs. 66%; p < 0.001) and
cannabis consumption (22% vs. 50%; p < 0.001) were more
frequent among men. Ten years later, women continued living
independently of parents (70% vs. 45%; p < 0.001) and more
frequently had a partner (38% vs. 26%; p= 0.057). Schizophrenia
diagnosis (63% vs. 84%; p= 0.002) tobacco (45% vs. 61%; p= 0.02)
and cannabis consumption (4% vs. 12%; p= 0.038) continued to
be more frequent among men (See Table 1).
A group of 151 patients (85 female and 66 male) with clinical,
functional, neuropsychological, and antipsychotic treatment
information from assessments spanning the 10-year follow-up
period were included in the results below.
Positive, negative, and depressive symptoms in female and male
FEP patients over 10 years: five consecutive follow-ups
Results revealed positive symptoms were similar at baseline and
improved to about the same extent in males and females.
Repeated measures analysis of covariance (ANCOVA) (with age at
first contact as covariate) showed a significant within group by
time effect (F= 21.883; p < 0.001). However, no significant
between group by time effect was found.
Females showed more pronounced improvements (F= 8.135;
p < 0.001) of negative symptoms than males. Significant between
group by time (F= 9.33; p= 0.003) and within group by time
differences were found at 6-week (F= 13.15; p < 0.001), 3-year
(F= 6.131; p= 0.014) and 10-year (F= 5.983; p= 0.016) Scale for
the Assessment of Negative Symptoms (SANS) assessments.
Significant within group by time (F= 4.665; p= 0.032) but not
significant between group by time effect was found for depressive
symptoms, which evolved in parallel among male and female FEP
patients (See Fig. 2).
Functionality and global cognitive function in female and male
FEP patients over 10 years
Disability Assessment Scale (DAS) and global cognitive functioning
(GCF) did not reveal either within group by time or between group
by time effects. Exclusively years of education showed a significant
group by time effect for GCF (F= 13.33; p= 0.001) (See Fig. 3).
Sex differences in relapses and recovery across time
Information on relapses was obtained for 142 patients (61 female
and 81 male). Survival curves showed that most of the relapses
occurred during the first 3 years of follow-up, with the curve
flattening out owing to a lack of events between 3- and 10-year
follow-ups. There was no significant difference (log-rank
[Mantel–Cox]χ²= 0.07; p= 0.792) between female and male
patients (See Fig. 4).
Recovery information at 10-year reassessments was available for
171 patients (75 female and 96 male). Of these patients, 26 females
(36.6%) and 21 males (22.3%) showed symptomatic and functional
recovery at 1-year follow-up (χ²= 4.049; p= 0.044); 36 females
(50%) and 28 males (30.8%) at 3-year follow-up (χ²= 6.234;
p= 0.013); and 35 females (46.7%) and 33 males (34.4%) at
10-year follow-up (χ²= 2.656; p= 0.103). (See Fig. 5).
Antipsychotic medication and extrapyramidal symptoms in female
and male FEP patients: analyses of seven consecutive follow-ups
Baseline, 3-month, 6-month, 1-year, 2-year, 3-year, and 10-year
treatment information was available for 91 patients (52 male and
39 female). Repeated measures ANCOVA (age as covariate)
revealed significant within group by time (F= 5.557; p= 0.021)
and age by time (F= 6.46; p= 0.013), as well as between group by
time effects (F= 12.184; p= 0.001). Significant differences in
equivalent chlorpromazine dosage arose at 6-month (F= 4.27;
p= 0.042), 1-year (F= 6.838; p= 0.01), 2-year (F= 11.533;
p= 0.001) and 3-year (F= 14.841; p < 0.001) assessments, showing
that females used lower therapeutic dosages. Minimal therapeutic
dosages were reached at the 3-year follow-up, but between 3- and
10-year follow-up an increase in dosage was observed for bothFig. 1 Flow diagram for study participants.
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male and female patients. Males and females did not significantly
differ on the occurrence of extrapyramidal symptoms (See Fig. 6).
DISCUSSION
This research examined sex differences in long-term outcomes
after an FEP. Our results suggest that better outcomes for women
found after 3 years of treatment at an EIS were underpinned by
the presence of more favorable premorbid and baseline
characteristics. After an average period of 10 years after treatment
initiation, outcomes for women and men converged, with the
exception of negative symptoms course. This draws particular
attention to the increased dosage of antipsychotic medication for
both sexes once they were discharged from the EIS program
toward community-based services.
It could be said that women presented better functioning in
terms of attaining milestones of adulthood such as completing
school, having employment, leaving home, marrying, and having
children. However, most of these circumstances were already
present at illness onset, which might lead to the suggestion that
women have an advantage in coping with difficulties associated
with schizophrenia3. More women than men were partnered or
married because women, whose illness begins later, often marry
before their illness begins. Parenting was more common among
women as well8. Those findings are consistent with the existing
research of Hafner et al.10, supporting the mentioned advantages,
such as higher rates of marriage and children, and lower rates of
cannabis use. Seeman et al.3 found that despite women attaining
better outcomes, there is a dependence on the social and cultural
background of the study population. This is particularly the case in
the exhibited maintenance of meaningful occupations, universally
Table 1. Comparison of baseline and 10-year follow-up characteristics between male and female FEP patients.
Male Female
N= 114 N= 95
Characteristics Mean SD Mean SD Statistic Value p
Age at admission (years) 27.4 7.5 31.7 9.6 t −3.644 <0.001
Age at psychosis onset (years) 26.2 6.8 30.5 9.5 t −3.662 <0.001
Duration of illness (months) 29.2 34.4 22.7 38.1 t 1.280 0.202
Duration of psychosis (months) 13.6 27.7 13.8 32.2 t −0.056 0.956
Premorbid functioning 3.7 2.0 2.4 1.8 t 4.375 <0.001
Premorbid IQ 93.1 14.4 97.7 13.8 t −2.040 0.043
Hospitalization (days) 21.9 18.1 18.8 14.2 t 1.086 0.280
Baseline N % N % Statistic Value p
Diagnosis schizophrenia (yes) 79 69.3 49 51.6 χ² 6.854 0.009
Race (white) 112 98.2 94 98.9 Fisher 1.000
Urban area (yes) 79 69.3 65 68.4 χ² 0.019 0.891
Socioeconomic status of parents (low) 63 55.8 50 53.2 χ² 0.136 0.713
Education level (elementary) 65 57.0 27 28.4 χ² 17.196 <0.001
Living with parents (yes) 69 60.5 40 42.1 χ² 7.047 0.008
Single (yes) 96 84.2 62 65.3 χ² 10.084 0.001
Children (yes) 15 14.0 36 40.0 χ² 17.199 <0.001
Unemployed (yes) 54 47.4 27 28.4 χ² 7.838 0.005
Student (yes) 23 20.2 22 23.2 χ² 0.273 0.601
Tobacco (yes) 71 62.3 47 49.5 χ² 3.457 0.063
Cannabis (yes) 58 50.9 21 22.1 χ² 18.245 <0.001
Alcohol (yes) 76 66.7 32 33.7 χ² 22.573 <0.001
Hospitalization (yes) 77 67.5 56 58.9 χ² 1.655 0.198
10Y
Diagnosis schizophrenia (yes) 84 84.0 53 63.9 χ² 9.781 0.002
Urban area (yes) 66 61.7 60 66.7 χ² 0.527 0.468
Living with parents (yes) 59 55.1 27 30.0 χ² 12.561 <0.001
Single (yes) 74 69.2 45 50.0 χ² 7.502 0.006
Children after FEP (yes) 8 7.5 12 13.3 χ² 1.838 0.175
Unemployed (yes) 35 32.7 22 24.4 χ² 1.624 0.202
Student (yes) 12 11.2 17 18.9 χ² 2.293 0.130
Tobacco (yes) 70 61.4 43 45.3 χ² 5.436 0.020
Cannabis (yes) 14 12.3 4 4.2 χ² 4.288 0.038
Alcohol (yes) 27 23.7 14 14.7 χ² 2.631 0.105
Hospitalization >1 (yes) 58 50.9 42 44.2 χ² 0.923 0.337
IQ intelligent quotient, FEP first episode of psychosis.
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seen as positive and more frequent among females. In the same
vein, both a higher age at illness onset of psychosis and better
premorbid adjustment for women, which are favorable conditions
for recovery, have been consistent findings11.
Having a first psychotic break at an older age is a positive
prognostic factor because it allows higher premorbid achieve-
ments, in terms of greater knowledge and experience in the world
before the illness, and time for the development of better social
skills and greater resilience12. This is also confirmed in the present
study concerning the higher education achievements and higher
premorbid IQs in females, in line with a former study in our
group13. Our study confirmed as well the replicated finding of
equivalent cognitive impairment among male and female FEP
patients14. It has been suggested that gender differences in
neuropsychological impairments are evident in bipolar/mania and
among depressive psychotic patients but with only minimal
effects in schizophrenia15.
Women showed a marked recovery between the first and third
year, but at 10 years the analysis of sex differences in functional
recovery did not reach statistical significance. A similar finding was
observed in a study carried out across diverse regions of the
world16. Novick et al.16 found that in Central and Eastern Europe
females showed higher rates of clinical remission at 36 months,
with no sex differences in functional remission and recovery.
Grossman et al.12, who studied recovery over a span of 20 years,
found that women showed significantly better global functioning
and higher percentages of recovery in the 2- and 10-year follow-
ups. Compared with 41% of the men, 61% of the women with
schizophrenia showed a period of recovery at some point during
the 20-year period. Dama et al.7 suggested that some men may
need more than 2 years of EIS to achieve good clinical outcomes
and effectively improve their overall functioning. We suggest that
patients receiving EIS beyond 3 years may continue to experience
further improvements in negative symptoms and functioning,
resulting in increased rates of recovery.
Women showed a consistent pattern of less severe and better
course of negative symptoms than men. Overall, this result is in
agreement with most of the published literature, wherein men
with schizophrenia appear to have more negative symptoms and
more severe clinical features, particularly in social withdrawal,
substance abuse, and blunted or incongruent affects than female
patients17. Hafner et al.10 proposed that the apparent vulnerability
of men to schizoid characteristics might explain, at least partially,
the increased negative symptom severity, earlier age of onset, and
worse overall social functioning. Younger age at illness onset in
men occurs concurrently with more negative symptoms18.
Women have advantages over men in that their illness starts at
later ages and their symptoms respond more quickly and more
completely to available treatments3. However, even when age of
onset was addressed by assessing a uniform sample (younger
than 40 years old), and when there was no sex difference in
premorbid adjustment, women showed a better course of
illness10. In general, females have lower levels of negative
symptom severity, lower rates of alcohol/substance abuse, and
higher percentages of having a spouse/partner and independent
living16. This may indicate that a healthy lifestyle, presence of a
spouse/partner, and having children are protective roles for
females against negative symptoms.
This study provides new evidence to what happens with
antipsychotic treatment when patients are discharged from EIS
programs towards routine outpatient mental healthcare services.
Females particularly showed an increase in dosage. Effective doses
of antipsychotics in women may have to be lower than
recommended for men, especially with regards clozapine and
olanzapine, and it is evident that some antipsychotic side effects,
such as weight gain, are more worrying for women19. Women may
be more vulnerable than men to adverse reactions because the
recommended doses in the market are calculated for a 70 kg
(154 lb) man20. The ability of women to respond to lower doses
has been attributed to the effects of female hormones on the
absorption and metabolism of antipsychotic medications, and to
their relatively greater blood flow in the brain bringing more drug
to receptors21. Brain structure, genetic and hormonal differences
play a role on metabolic, cardiovascular, inflammatory, and
immune parameters explaining sex differences in response to
antipsychotics20. Seeman et al.22 suggested that the dosage
intervals for women should be longer than for men. Furthermore,
a recent review suggests that adjuvant estrogen may make
treatment more effective and may reduce the dose of anti-
psychotics and, therefore, help to prevent side effects23. This
applies to both sexes, but is especially applicable to women.
Women require more thorough follow-up, including bone density
scans, electrocardiograms, and mammograms. Meanwhile, the
Fig. 2 Clinical outcomes over follow-up in males and females.
Fig. 3 Functional and cognitive outcomes over follow-up in males
and females.
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minimal effective dose of antipsychotics should always be
selected. We found no differences in extrapyrimidal symptoms
between male and female patients, which makes medication
adjustments very important. Effective treatment means eliminat-
ing symptoms and improving function, but also the absence of
side effects.
As expected, based on literature and in previous research in our
group, females were older at illness onset and admission to the
PAFIP program4,14. Mean age at onset for females was 4 years
higher than that for males. This finding is consistent with the
nationwide assessment of life time risks for mental disorders
conducted in Denmark. Paying attention to sex- and age-specific
incidence rates, and sex- and age-specific cumulative incidences
of mental disorders treated in secondary care during a full life
time, Pedersen et al.24 found that both sexes had almost identical
incidence rates and cumulative incidences for schizophrenia
during childhood and adolescence, but from 20 to 50 years of
age, males had higher incidence rates and cumulative incidences.
However, when Thorup et al.25, also in Denmark, extended the age
range up to 71 years, they found that males had the highest
incidence rates from age 17 to 40, whereas females had the
highest incidence rates from age 50 to 68, confirming that male
sex is a major risk factor for the development of schizophrenia but
showing that risk for women increases with increasing age. They
suggest that traditions in the diagnosis system (the narrowing of
the diagnostic criteria leads to more women being excluded from
a diagnosis of schizophrenia), and reluctance in some clinicians to
use the diagnosis of FEP in elderly people lead to biases that
should be avoided in the future.
To our knowledge, there are no other published longitudinal
studies that have explored sex differences in such long-term
Fig. 4 Survival curves of relapse over time in males and females.
Fig. 5 Recovery percentages in males and females over time. Fig. 6 Chlorpromazine doses and Sympson–Angus scores over time
in males and females.
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outcomes among FEP patients after being in an EIS program. Most
of the studies have been conducted in one of three ways, such
that patients were sampled from chronic patients, were matched
for sex, or were statistically controlled for sex in the analyses. To
overcome this limitation, we focused our analyses on sex
differences in FEP patients. Regretfully, the current analyses did
not explore the relative contributions of biological (i.e., plasma
level of estrogen), psychosocial (i.e., resilience) and environmental
factors to the sex differences and their interplay, which clearly
warrants further research. The choice of better measures to assess
function, particularly concerning DAS, is not without its critics. DAS
is a quite an outdated measure, consisting of a criteria that does
not necessarily reflect the real functioning observed in out-
patients. Meanwhile, the follow-up in the PAFIP cohort was
scheduled for 3 years, at which point, the patients were
discharged from our EIS to community mental health services.
For the purpose of the present study, they were contacted within
a time window ranging from 8 to 16 years after enrolling in the
program. We cannot rule out the influence of information that was
not recorded but could have affected outcomes. Finally, our
findings concerning exitus corresponds with the results from a
recent published nationwide cohort study that included patients
admitted for the first time to hospital during 2000–2014 for
schizophrenia or schizoaffective disorder in Finland26. Sommer
et al.26 found that during the 10-year follow-up, mortality was
lower in women, with fewer suicide and cardiovascular deaths, but
more cancer deaths. A detailed exploration on exitus was not an
aim of the present study, although it is an important issue to
research in the future.
Neither sex has the monopoly on good outcomes. However,
women have certain advantages over men in that their illness
starts at a later age, providing them with more time to achieve
goals in life, which in turn results in better outcomes over the first
3 years of treatment in specialized programs. Yet, these benefits
for women appear to dissipate, particularly once they are
discharged from an EIS towards community-based services, a
transition that is accompanied by an increase in the doses of
antipsychotic medication. This pattern helps to pose the question
of whether it is wise to target the sexes and lengthen EIS
interventions. Exploring long-term sex differences in outcomes
among FEP patients could provide useful information to better
understand and to improve sex specific approaches to treat
psychosis.
METHODS
Study design and setting
This paper is based on data obtained from PAFIP and PAFIP-10, which are
incidence and 10-year follow-up studies, respectively, of all individuals with
an FEP presenting for the first time to mental health specialists in the
catchment area of Cantabria after February 2001 when a local EIS service
for psychosis was established.
PAFIP was designed as an epidemiological prospective cohort study and
a 3-year EIS program for FEP patients, conducted at the outpatient clinic
and the inpatient unit at the University Hospital Marques de Valdecilla,
Spain27. A multidisciplinary clinical team (three psychiatrists, two
psychologists, one psychiatric nurse, and one social worker) provided 3
years of evidence-based phase-specific EIS for psychosis: low dose of
antipsychotic medication while monitoring side effects, psychoeducation
for patients and their families, and support for functional recovery based
on return to normal daily activities (work/study) while expecting full
recovery. Besides their routine visits in order to check symptoms and
compliance with treatment, patients were contacted by telephone to
schedule face-to-face appointments at 1- and 3-year follow-ups.
The PAFIP-10 study included FEP patients that were referred to the
PAFIP program between February 2001 and December 2008. The patients
constituting the 10-year follow-up PAFIP cohort were reassessed between
June 2014 and August 2018. The patients included in the referred period
were invited for a reassessment after a time window ranging from 8 to 16
years after initial presentation4.
Ethical considerations
The PAFIP program was publicly funded by the regional Mental Health
Services. Its research protocol was approved by the local Research Ethics
Committee (CEIm of Cantabria) in accordance with international standards
for research ethics (NCT0235832 and NCT02534363). Patients that met
criteria for inclusion along with their families provided written informed
consent for entry into PAFIP and for PAFIP-10 reassessment4.
Subjects
The PAFIP-10 sample comprised all referrals to PAFIP between 2001 and
2008 that had been screened against the following inclusion criteria: age
15–60 years; living in the catchment area; experiencing their first episode of
psychosis; no prior treatment with antipsychotic medication or, if previously
treated, a total life time of adequate antipsychotic treatment of <6 weeks;
meeting DSM-IV criteria (APA, 2000) for brief psychotic disorder, schizo-
phreniform disorder, schizophrenia, or schizoaffective disorder. DSM-IV
criteria for drug or alcohol dependence, intellectual disability, and having a
history of neurological disease or head injury were exclusion criteria.
Measures
This information has been previously reported in Ayesa-Arriola et al.,4.
Baseline sociodemographic and clinical variables were obtained for a sample
of 307 FEP patients (128 female and 179 male). Premorbid and socio-
demographic information was recorded from interviews with patients, their
relatives and from medical records on admission. Other baseline and
demographic variables included: Sex, age, age at psychosis onset (defined as
the age when the emergence of the first continuous psychotic symptom
occurred), duration of untreated disease (DUI: defined as the time from the
first nonspecific symptoms related to psychosis to the start of adequate
treatment with antipsychotic medications, without return to the previous
level functioning), duration of untreated psychosis (DUP: defined as the time
from the first continuous psychotic symptoms to the start of appropriate
treatment with antipsychotic medications), and premorbid social adjustment
(measured using the Premorbid Adjustment Scale28, wherein the rating of 0,
indicates “better”, and the rating of 6 denotes “worse”).
Baseline and 10-year characteristics were recorded, including: education
level according to the Spanish educational system (“low” vs. “medium and
high”), total years of education, socioeconomic status derived from the
parents’ occupation (“low qualification worker” vs. “other”), living area
(“urban” vs. “rural”, defined as more or <10,000 inhabitants, respectively),
relationship status (“married/cohabiting” vs. “single/divorced/separated or
widowed”), living status (“alone” vs. “other”), employment status
(“employed” vs. “unemployed”), first-degree family history of psychosis
based on subject and family reports (“yes” vs. “no”), as well as tobacco,
alcohol and cannabis consumption (“yes” vs. “no”).
Clinical and functional instruments
This study utilized clinical and functional data collected at four different points
throughout the follow-up period. The same senior consultant psychiatrist (BC-
F) interviewed patients at baseline, 1-, 3-, and at 10-year follow-up. Baseline
diagnoses were assigned using the Structured Clinical Interview for DSM-IV
(SCID-I)29 6 months after the baseline visit. Based on follow-up information,
diagnosis stability vs. change were considered at 10-year reassessment.
Clinical symptoms of psychosis were assessed by the SANS30 and the Scale
for the Assessment of Positive Symptoms (SAPS)31. SAPS and SANS sub-scales
were divided into positive (scores for hallucinations and delusions),
disorganized (scores for formal thought disorder, bizarre behavior and
inappropriate affect) and negative dimensions32 (scores for alogia, affective
fattening, apathy and anhedonia). General psychopathology was assessed
with the Brief Psychiatric Rating Scale (BPRS)33. Depressive symptoms severity
was measured using the Calgary Depression Scale for Schizophrenia (CDSS)34.
Global functioning was measured by the DAS Spanish version35 on every
assessment. The DAS was specifically designed for psychiatric populations
and assesses the functioning status during the previous 30 days. This tool
is a semi-structured interview that assesses several areas of functioning:
self-care, social withdrawal, participation in the household, relationship
with spouse or partner, occupational role and general interest. These areas
are rated on a 6-point scale: 0, no disability; 1, minimum disability; 2,
obvious disability; 3–5, serious to maximum disability.
A measure of GCF was calculated in accordance to previous methodol-
ogy36. Scores on the seven cognitive domains fundamentally impaired in
psychosis were converted to T-scores derived from a healthy comparison
R. Ayesa-Arriola et al.
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sample, and converted to deficit scores that reflected presence and severity
of cognitive deficit on each cognitive domain. Deficit scores were then
averaged to create the GCF measure.
Recovery, comprising symptomatic remission, and adequate psychoso-
cial function at 1-, 3-, and 10-year follow-up, was determined by scores of 2
or less in the corresponding items of the SANS and the SAPS scales, as
established by the remission work group37, and a score of 1 or less in the
DAS scale38,39. Information about number of relapses during the 10 years
were also considered, as well as mean antipsychotic daily doses (converted
to chlorpromazine equivalents40) at seven different assessment points
(baseline, 3 months, 6 months, 1 year, 3 years, and 10 years).
Extrapyramidal symptoms were reported using Sympson–Angus Scale41
at baseline, 6 weeks, 1 year, 3 years, and 10 years.
Statistical analysis
The Statistical Package for Social Science, version 19.0 (SPSS Inc., Chicago,
IL, USA), was used for statistical analyses. All tests were two-tailed and the
significance level was set at 5%.
Group differences for continuous variables were evaluated with t tests.
Chi-squares were used for categorical variables. General Linear Models
with repeated measures ANCOVAs were conducted to test longitudinal
outcomes among male and female FEP patients. Bonferroni corrections
were used to control for multiple comparisons. Post hoc comparisons
presented in tables and figures for each dependent variable include only
those cases with valid data on all of the variables at all time points.
Kaplan–Meier survival analysis, along with the log-rank test, was used to
examine the relationship between relapses and time.
Reporting summary
Further information on experimental design is available in the Nature
Research Reporting Summary linked to this paper.
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